Details
Description
Gonadotropin-releasing hormone (GnRH) agonist products are indicated for a variety of conditions, such as central precocious puberty, breast cancer, prostate cancer, and endometriosis. The utilization of GnRH agonist products among U.S. adolescents is not well-characterized in the current literature.
This poster assesses GnRH agonist product use in adolescents and identifies possible diagnoses associated with their use. It was presented at the 39th International Conference on Pharmacoepidemiology and Therapeutic Risk Management.
Additional Information
Contributors
Presenter(s)
Corinne Woods, Amy Ho, Rebecca Hawrusik, Ryan Schoeplein, Sarah K. Dutcher, Adebola Ajao, David Moeny, Ting-Ying Huang